Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Topiramate - Janssen

Next Previous
Drug Profile

Topiramate - Janssen

Alternative Names: Epitomax; KW-6485; KW-6485P; MCN 4853; RWJ 17021; Topamax; Topamax Migraine; Topimax; Topina; Topina fine granules

Latest Information Update: 19 Nov 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Johnson & Johnson Pharmaceutical Research & Development
  • Developer Janssen Inc; Janssen Research & Development; Janssen-Cilag; Johnson & Johnson Pharmaceutical Research & Development; Johnson & Johnson Pharmaceutical Research & Development LLC; Kyowa Kirin; Ortho-McNeil; Xian-Janssen
  • Class Antiepileptic drugs; Antimigraines; Dioxolanes; Hexoses; Ketoses; Neuroprotectants; Obesity therapies; Pyrans; Small molecules; Sulfonic acids
  • Mechanism of Action AMPA receptor antagonists; Carbonic anhydrase inhibitors; GABA A receptor agonists; GABA A receptor antagonists; Kainic acid receptor antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Epilepsy; Lennox-Gastaut syndrome; Migraine
  • No development reported Post-traumatic stress disorders
  • Discontinued Bipolar disorders; Diabetic neuropathies; Obesity

Most Recent Events

  • 19 Nov 2024 Discontinued - Phase-III for Obesity (In adolescents, In children) in France (PO) (EudraCT2011-006193-36) (NCT02273804)
  • 04 Dec 2023 m8 Pharmaceuticals has been acquired by Acino
  • 08 Apr 2021 No development reported - Phase-III for Obesity (In adolescents, In children) in France (PO) (NCT02273804) (EudraCT2011-006193-36)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top